title: Long-term effect of a single dose of flunarizine in Huntington's disease.
abstract: We report a preliminary pilot study on the clinical efficacy of flunarizine (FNZ), a calcium-entry blocker that causes extrapyramidal side-effects, in 10 patients with Huntington's disease (HD). FNZ (20 mg) administered by the sublingual route resulted in a decrease in choreic movements and improved dexterity in performing several tests. These effects lasted for at least 7 days after a single dose. Therefore, FNZ seems to exert the same effect as a long-acting neuroleptic agent in our HD patients.Copyright Lippincott-Raven Publishers
authors.affiliation: Department of Neurology, Ospedale Civile Vito Fazzi, Lecce, Italy.
authors.initials: G
authors.lastname: Belfiore
authors.lastname: Di Maio L
authors.initials: G
authors.lastname: Napolitano
authors.initials: S
authors.lastname: Cella
authors.initials: A
authors.lastname: Filla
authors.lastname: De Michele G
authors.initials: G
authors.lastname: Campanella